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The qk
v mutation is a one megabase deletion resulting in abnormal expression of the qkI gene. qk
v mice
exhibithypomyelinationofthecentralnervoussystemanddisplayrapidtremorsandseizuresasadults.The
qkIlocuson6q26-27hasalsobeenimplicatedasacandidatetumorsuppressorgeneastheqkIlocusmapsto
a region of genetic instability in Glioblastoma Multiforme (GBM), an aggressive brain tumor of astrocytic
lineage. As GBM frequently harbors mutations affecting p53, we crossbred qk
v and p53 mutant mice to
examine whether qk
v mice on a p53
2/2 background have an increased incidence of GBM. qk
v/v; p53
2/2 mice
hadareducedsurvivalratecomparedtop53
2/2littermates,andthecauseofdeathofthemajorityofthemice
remains unknown. In addition, immunohistochemistry revealed Purkinje cell degeneration in the
cerebellum. These results suggest that p53 and qkI are genetically linked for neuronal maintenance and
survival.
T
he study of neurological diseases has been greatly advanced with the use of mouse models. In particular,
spontaneously occurring mutant mice have played an important role in identifying key components
required for proper myelination. One such mouse, the autosomal recessive qk
v mutant, was first described
in 1964 by Sidman and colleagues. The qk
v/v mouse exhibited severe hypomyelination of the central and peri-
pheral nervous system and severe hindlimb shaking
1. The mutation responsible for the qk
v/v phenotype was later
identified as a one megabase deletion that results in loss of parkin (park2) and parkin co-regulated (pacrg)
function, whereas qkI expression becomes abnormally expressed
2–4.I nqk
v/v mutants, qkI-6/7 expression is
preferentially lost in myelin producing cells of the central and peripheral nervous systems, while for the most
part expression remains unaffected in all other cell types
3. The qkI gene encodes for the alternatively spliced KH
domain RNA binding proteins QKI-5, -6, and -7
5. QKI has been shown to regulate important mRNA targets
involved in myelination and oligodendrocyte differentiation
6–11. QKI is implicated in myelinogenesis by stabil-
izing myelin basic protein (MBP) mRNA
6,12, regulating the alternative splicing pattern of myelin associated
glycoprotein (MAG)
10,13, and oligodendrocyte differentiation and Schwann cell differentiation
7,14. The over-
expression of QKI-6 in qk
v mutants has been shown to rescue the myelination defect
15.
In addition to myelination defects, qk
v mice also exhibit ciliopathies including male sterility and mild hydro-
cephalus
16–17. Cilia lining the ventricles of the brain are responsible for proper circulation of cerebral spinal fluid
(CSF). Ciliogenesis is normal in qk
v mice, however the cilia are functionally impaired leading to decreased CSF
flow and hydrocephalus
16. Hydrocephalus in qk
v mice becomes fatal on a patched1 (ptch1) heterozygous back-
ground
18.
Thelongarmofchromosome6isknowntoharboracommonfragilesitethatisfrequentlylostormutatedina
varietyofcancers
19–20.Thebreakpointincludesseveralgenes,oneofwhichhasbeenidentifiedastheqkIgene
21–22.
Chromosomalaberrationsat6q26-27arecommoninGlioblastomaMultiforme(GBM)
21.Inadditiontomapping
to a region of genomic instability, expression of qkI mRNA transcripts have been shown to be altered specifically
in human gliomas compared to other brain cancers
23. Thus, it has been proposed that QKI may function as a
tumorsuppressorandplayaroleinGBMprogression.EvidenceforasuppressorrolewasshownfortheC.elegans
GLD-1, a QKI homolog
24. The GLD-1 C. elegans homolog of QKI is known to associate with the p53 cep-1
mRNA, influencing its activity
25. In addition, QKI was discovered to be down-regulated in colorectal cancers
26.
QKI over-expression in the colon epithelium resulted in increased levels of p27
kip1 as well as an increase in
membrane bound b-catenin, an indicator of gastric cell differentiation
26. These observations along with our data
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7, a property often observed for
tumor suppressors, suggest that the absence of QKI proteins may
promote tumorigenesis.
Lossofheterozygosityandmutationsofthep53geneiscommonly
associated with a variety of cancers in multiple organ sites
27. Indi-
viduals with the Li Fraumeni syndrome, in part caused by mutations
in the p53 gene, suffer from early onset of many different types of
cancer
28. Mutations abrogating p53 function and allelic loss of chro-
mosome 17p were among the first genetic lesions identified in
GBM
29. p53 lesions are present in all grades of astrocytoma at an
average of 30%
30, suggesting that the inactivation of p53 is an early
event in gliomagenesis. p53
1/2 and p53
2/2 mice have been found to
develop a broad spectrum of tumors, including lymphomas, osteo-
sarcomas, and fibroscarcomas
31. p53
1/2 and p53
2/2 mice have been
used as a background strain to breed with other mutant strains to
produce entirely novel tumor spectrums that were not found in
mice with a mutation in p53 alone
32. Although p53
1/2 mice showed
no incidence of any brain malignancy
31,33, nf1
1/2; p53
1/2 mice
developed astrocytomas with a penetrance of 92% by 6 months of
age
34.
Here we report that qk
v/v mice on a p53
2/2 background had a
reduced survival rate compared to qk
v/1; p53
2/2and p53
2/2 controls,
andthe causeof deathof themajority of themice remains unknown.
qk
v/v; p53
2/2 mice also displayed neurological defects including
Purkinje neuron degeneration.
Results
The qk
v/v mice contain a recessive autosomal mutation of ,1.1 Mb
onchromosome17affectingtheexpressionofquaking(qkI),parkin-
coregulated gene (pacrg) and parkin (park2)
4. The mutation results
inaberrantexpressionofalternativelysplicedqkItranscripts,leading
to the dysmyelination defects observed in the qk
v/v mice
4. Deletion
of the pacrg gene in qk
v mice causes ciliopathies including hydro-
cephalus
16 and male sterility
35. To examine whether the p53 pathway
geneticallyinteractswiththepacrg-parkin-qkIlocusintheregulation
of the phenotypes of the qk
v/v mice, we crossbred the qk
v/v mice with
p53 null mice. We initially assessed the myelin sheath of resulting
qk
v/v;p53
2/2progeny. Post-natal day 30(P30)coronal sections of the
corpus callosum were stained with an antibody specific to myelin
basic protein (MBP). As expected, qk
v/v mice showed reduced thick-
ness of the corpus callosum (98.8 6 16.4 mm) compared to wild-type
(wt) (172.76 7.03 mm) and qk
v/1; p53
2/2 (191.8 6 5.99 mm) litter-
mates (Figure 1). However, qk
v/v; p53
2/2 mice did not show an
increased severity of hypomyelination compared to qk
v/v mice (86.9
6 8.89 mm, Figure 1), and corpus callosum thickness was not found
to be statistically different between the mice (p 5 0.287). Although
corpus callosum thickness was reduced in mice with the qk
v muta-
tion, sparse high intensity MBP staining was observed along the
myelin tracts. These MBP-positive ‘‘blebs’’ have previously been
observed in spinal cord white matter of qk
v/v mice, corresponding
to redundant loops of uncompacted myelin
36. These results suggest
that p53 does not cooperate with qkI in the regulation of myelin
formation in vivo. The loss of both wt p53 alleles did not affect the
onsetofhindlimbshakinginmicepups,sincebothqk
v/v;p53
2/2mice,
qk
v/v; p53
1/2 mice and qk
v/v mice displayed tremors by P14 (data not
shown). Common husbandry procedures and animal handling are
sources of acute stress and elicit tonic clonic seizures in qk
v mice
37–39.
Theonsetofstressinducedtonic-clonicseizuresinqk
v/v;p53
2/2mice
was significantly earlier than that of qk
v/v mice. qk
v/v mice began
demonstrating stress-induced seizures at 12 weeks of age, whereas
qk
v/v; p53
1/2 mice and qk
v/v; p53
2/2 mice were observed to have sei-
zures and ataxic movements as early as 4 weeks of age (data not
shown). As expected, mice heterozygous for the qk
v mutation did
not demonstrate tonic-clonic seizures or hindlimb shaking.
WeassessedthecellularmorphologyofPurkinjecellsbyimmuno-
staining P30 coronal brain sections with an antibody against
Calbindin, a Purkinje neuron-specific marker. Immunostaining of
the brains of qk
v/v; p53
2/2 mice revealed Purkinje cell body loss as
well as loss of Calbindin-positive Purkinje cell dendritic arbors,
whereascontrolmicedemonstratednormalPurkinjecellappearance
Figure 1 | qk
v-associatedhypomyelination isnotexacerbated onap53
2/2
background. Brains were frozen over acetone-dry ice and cryostat
sectionedatathicknessof10mm.Coronalsectionsofageandsex-matched
mousecortexes were stained withanti-MBP antibody. Scale barrepresents
100 mm.
Figure 2 | qk
v/v;p53
2/2micedisplayPurkinjecelldefects. (A)qk
v/v;p53
2/2
mice display Purkinje cell body and dendritic arbor loss at P30 (arrows),
whereas control littermates exhibit normal cerebellar architecture.
Sections were stained with anti-Calbindin antibody. Scale bar represents
50 mm. (B) qk
v/v; p53
2/2 show normal Purkinje cell morphology of the
cerebellum at P14. Coronal sections of the cerebellum were stained with
anti-Calbindin antibody. Scale bar represents 50 mm.
www.nature.com/scientificreports
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cell numbers, we analyzed the Purkinje cell linear density of
P30 mice. qk
v/v; p53
2/2 mice were found to have a significantly
lower Purkinje cell density (16.36 6 1.42 cells/mm) compared with
wt (38.77 6 2.52 cells/mm; p , 0.001), qk
v/1; p53
2/2 (42.45 6
6.5 cells/mm; p 5 0.006), and qk
v/v controls (40.16 6 7.9 cells/mm;
p 5 0.01). Misplaced Purkinje neurons have occasionally been
observed in qk
v/v mice
40. To determine if the Purkinje defects
observed were due to impaired migration or other developmental
defects, immunostaining was performed on brains of P14 mice.
Purkinje cell morphology was normal in qk
v/v; p53
2/2 P14 mice,
suggesting that Purkinje cell loss was not due to failure in neuronal
migration at earlier stages of development (Figure 2B). These results
suggest that the Purkinje cell defects observed in qk
v/v; p53
2/2 mice
were not due to impaired development, but cell body and dendrite
degeneration and defects in neuronal maintenance and survival.
Indeed, qkI has been shown play a role in apoptosis in 3T3 mouse
fibroblasts, HeLa cells, and primary rat oligodendrocytes
41–42.
p53
1/2micedevelopprimarilysarcomas,withanincidenceof28%
over 17 months. p53
2/2 mice have a much accelerated rate of tumor-
igenesis, with the majority of mice succumbing to lymphomas by six
months of age
31. qkI has been implicated as a candidate tumor sup-
pressor gene as the qkI locus maps to a region of genetic instability
in GBM
22, therefore we examined whether qk
v/v; p53
2/2 mice would
display a higher incidence of brain tumors and thus may die earlier
than mice deficient for p53 alone. Kaplan-Meier curve analysis was
performed in order to compare mouse survival rates (Figure 3A).
In agreement with previous observations
1, none of the qk
v/v mice
cohort succumbed to tumor formation at the end of the 261 day
observation period. Overall, qk
v/v; p53
2/2 mice were found to have
areducedsurvivaltimecomparedtotheothergroups,withamedian
survival time (MST) of 119 days. qk
v/v; p53
2/2 mice showed a signifi-
cantlyreducedsurvivaltimecomparedtoqk
v/1;p53
2/2mice(MST5
142 days; p 5 0.0135) as well as p53
2/2 mice (MST 5 172 days; p 5
0.0443) according to the log rank/Mantel Cox test. There was no
significant difference between the survival rates of qk
v/1; p53
2/2and
p53
2/2 mice according to the Mantel Cox test (p 5 0.9175).
Previous studies have shown that the majority of p53
2/2 mice
develop tumors of the lymphatic system and soft tissue sarcomas,
with only one instance of a brain tumor reported in a p53
1/2
mouse
31,33. Similarly, the p53
2/2 and qk
v/1; p53
2/2 mice we generated
developed primarily sarcomas and lymphomas, with no occurrence
Figure 3 | qk
v/v homozygous mice show a reduced survival rate in the absence of p53. (A) qk
v/v; p53
2/2 mice (n 5 18) were observed to have a median
survival time of 119 days, significantly lower compared to qk
v/1; p53
2/2 mice (142 days, n 5 18) and p53
2/2mice (172 days, n 5 11) according to the log
rank/Mantel Cox test (p 5 0.0135 and p 5 0.0443, respectively). The loss of survival was measured by mice that were found dead or that had to be
sacrificed due to illness according to the guidelines of the Canadian Animal Care Committee. (B) Low-power magnification showing macroscopic
appearance of medulloblastoma occurring in the cerebellum, with an arrow denoting the tumor area. Higher magnification of medulloblastoma,
demonstrating the invasion of the molecular layer by the over proliferation of granular like tumor cells. Section was stained with H&E.
Immunohistochemistry performed on the medulloblastoma reveals tumor reactivity to GFAP, NFH, and CD31, specific markers for different cell
lineages.
www.nature.com/scientificreports
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v/v;
p53
2/2mice demonstrated any occurrence of sarcomas, lymphomas,
or tumors previously described in p53
2/2 mice (Table 1). Several
qk
v/v;p53
2/2andqk
v/v;p53
1/2mice displayedneurological symptoms
characteristic of hydrocephalus. Brains examined from these mice
showed enlarged lateral ventricles with an accumulation of CSF,
similar to the hydrocephalic phenotype observed in qk
v/v; ptch1
1/2
mice
18. The brain of one qk
v/v; p53
2/2 mouse showed increased vas-
cularization of the cerebellum and abnormal gross cerebellar archi-
tecture. Further histological analysis of cerebellar sections revealed
granule cell layer invasion of the surrounding parenchyma, consist-
ent with medulloblastoma (Figure 3B). Cytological analysis con-
firmed the presence of medulloblastoma, as tumor cell nuclei were
densely packed and polygonal in shape. Tumor cells were also found
to express markers of astrocytic (GFAP), neuronal (NFH) and vas-
cular (CD31) lineage (Fig. 3B). Cells expressing markers of multiple
lineages indicate cells of a stem cell precursor nature, consistent
with primitive neuroectodermal tumors such as medulloblastoma.
Medulloblastoma has not previously been observed to occur sponta-
neously in either p53
2/2 or qk
v/v mice
1,31. One study identified only
one instance of a brain malignancy out of a cohort of p53
1/2 mice
(n 5 40), whereas another study did not observe any tumors of the
nervous system in a cohort of p53
2/2 mice (n 5 35) or p53
1/2 (n 5
96) mice
31,33. The one p53
1/2brain tumor identified was an ependy-
moma,atumororiginatingfromthewallsoftheventricularsystem
43.
p53 mutations contribute to approximately 10% of human medullo-
blastoma cases
44; in addition, many mouse models of medulloblas-
toma have been developed by the combination of a specific tumor
suppressor mutation and the loss of p53
32. Although qkI has been
mapped to the common fragile site 6q25-26in GBM, loss of 6q25-26
in medulloblastoma is rare
45, suggesting that somatic qkI mutations
inclinicalmedulloblastomadonotconferanyspecifictumorigenetic
advantage. QKI has been shown to be expressed in post-natal neural
progenitor cells of the SVZ
46, suggesting that QKI may also be
expressed in other populations of multi-potent precursor cells
including the rostral rhombic lip progenitor cells that give rise to
granule neuronal precursor cells. It has not been determined if the
qk
v mutation affects QKI expression in neural progenitor cells
including granule neuronal precursor cells, therefore it remains a
possibilitythatthelossofqkI-6/7intheabsenceofp53couldprovide
sufficient oncogenic stress to induce transformation.
Discussion
Our study indicates that qk
v/v; p53
2/2 mice do not have decreased
corpus callosum thickness or MBP-staining compared to qk
v/v litter-
mate controls, suggesting that the qk
v-associated myelination defect
is not further impaired by the loss of p53. These findings indicate
that qkI does not cooperate with p53 in vivo to regulate the oligo-
dendrocyte differentiation pathway. qk
v/v; p53
2/2 mice displayed
Purkinje-cell defects in the cerebellum characterized by dendritic
arborizationdefectsandcellbodyloss,suggestingthatqkIisrequired
for neuronal cell maintenance in the absence of p53. However, the
exact mechanism by which this phenotype occurs has yet to be
elucidated. Cerebellar defects have previously been documented in
mice homozygous for the qk
v mutation. Three month old qk
v/v mice
displayed axonal swellings in both the Purkinje and granular cell
layer, indicative of axonal injury
40. Axonal swelling is characteristic
ofinflammatorylesionsinMultipleSclerosisandexperimentalauto-
immune encephalitis, suggesting that axonal pathology is secondary
to myelination defects
48–49. While our work showed that the qk
v
dysmyelinating phenotype was not exacerbated on a p53
2/2 back-
ground,Purkinjecelldegeneration wasonlyobservedinqk
v/v;p53
2/2
mice and not qk
v/v controls, suggesting that the neuronal pathology
was not due to myelination defects. Interestingly, qk
v/v; p53
2/2 mice
displayedstress-inducedtonic-clonicseizuresandataxicmovements
at about one month of age that was not observed in their qk
v/v coun-
terparts. Disruption in normal cerebellar architecture is one cause
of ataxia
50, thus Purkinje cell degeneration may be related to the
ataxic-like phenotype observed in qk
v/v; p53
2/2 mice. Indeed, 29
QKI-interacting partners were identified in a protein interaction
network generated for human inherited cerebellar ataxias
51.
qk
v/v;p53
2/2mice failed todeveloptumorscharacteristicofp53
2/2
mice, but demonstrated a reduced survival rate compared to both
qk
v/1; p53
2/2 and p53
2/2 mice. One case of medulloblastoma was
documented in a cohort of qk
v/v; p53
2/2mice (n 5 11), while 2 other
micedemonstratedsignsofhydrocephalus.Recently,wehaveshown
that qk
v/vmice on a ptch1
1/2background have a reduced survival rate
due to the development of fatal hydrocephalus
18. A mild hydroce-
phalic phenotype occurs in qk
v mice due the loss of PACRG express-
ionintheciliatedependymalcellsliningtheventricularwalls,leading
to cilia dysfunction
16. Similarly, qk
v/v; ptch1
1/2 mice showed abnor-
mal cilia function, leading to accumulation of CSF in the ventricles
and hydrocephalus
18.
The majority of p53
2/2 and qk
v/1; p53
2/2 mice in our study suc-
cumbed to thymic lymphoma, demonstrating clear symptoms
including difficulty breathing due to tumor-induced compression
of the lungs, enlarged ribcages, and lethargy due to tumor burden.
Necropsy of these mice revealed highly vascularized, enlarged thy-
muses that completely encompassed the heart and the majority of
the lungs, and in some instances, extended outside the ribcage into
the subcutaneous layers. These symptoms were not observed in
any of the qk
v/v; p53
2/2 mice before death, and necropsy revealed
normal thymic morphology. In addition, necropsy of qk
v/v; p53
2/2
mice did not reveal the presence of any overt cancers. Thus, the
cause of death of the majority of the mice remains undetermined.
Several possible explanations exist for the reduced survival rate
observed in qk
v/v; p53
2/2 mice. The qk
v/v mutation results in brain-
specific loss of qkI isoforms -6/7, resulting in preferential sensitiza-
tion of the nervous system to tumorigenesis in the absence of p53.
As mentioned earlier, our post-mortem pathological observation
methods were limited, thus it is possible that qk
v/v mice developed
additional brain tumors that remained undetected, including
medulloblastomas. Although we suspect that qkI and p53 participate
in different signaling pathways since double mutant qk
v/v; p53
2/2
mice displayed a novel phenotype not observed in either parent
strain,abioinformaticsanalysishasidentifiedp53asaputativetarget
ofQKIinmice.Thep53mRNAharborsaputativeQRE(QUAKING
Response Element) within its 3’UTR (UACUAACnnnnGAAG)
47.
These findings indicate that QKI may regulate p53 mRNA levels
in vivo. Consistent with these findings, the C. elegans homolog of
Table 1 | Tumors in qk
v/v; p53
2/2 mice
a
Genotype Total no. of mice Brain tumors Hydrocephalus Subcutaneous tumors Thymic lymphoma Intraperitoneal tumors Other
qk
v/v; p53
2/2 11 1(11%) 2(18%) 0 0 0 0
qk
v/v; p53
1/2 33 0 5(15%) 0 0 0 0
qk
v/1; p53
2/2 12 0 0 2(15%) 8(61%) 3(23%) 0
p53
2/2 9 0 0 0 5(55%) 3(33%) 1(11%)
a. tumors were classified according to tumor location.
www.nature.com/scientificreports
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regulate its activity
25.
In conclusion, QKI proteins are highly conserved among species
and have been implicated in multiple diverse biological pathways,
highlighting the pivotal role of RNA binding proteins in cellular
function. Our data suggests that qkI interacts with p53 in vivo to
regulate neuronal maintenance and survival.
Methods
Antibodies. Monoclonal MBP and NFH antibodies were obtained from Sternberger
Monoclonals (Baltimore, MD). Monoclonal Calbindin-D-28K and GFAP antibodies
were purchased from Sigma (St. Louis, MO). Anti-CD31 was purchased from
Millipore (Billerica, MA). Antibodies against QKI-5,-6, and -7 were generated as
described previously
7,42.
Animals. Mice were monitored daily and were handled and sacrificed in accordance
with a protocol approved by the Animal Care Committee at McGill University. The
mice were housed in ventilated cages with a 12/12 hour light/dark cycle. p53
2/2 mice
(lab stock # 002101) and qk
v mice (lab stock # 000506) were obtained from The
Jackson Laboratory (Bar Harbor, ME). Mice colonies were maintained on a C57BL/6
background. Mice homozygous for the p53 mutation were crossbred to heterozygous
qk
v mice and subsequent trans-heterozygous crosses were used to generate qk
v/1;
p53
2/2 males. These males were subsequently crossbred to trans-heterozygous
females to generate double mutant mice. Mice were screened for the p53 wild-type
alleleviagenomicPCRusingoligonucleotides(59-ATAGGTCGGCGGTTCAT-39)
and (59-CCC GAG TAT CTG GAA GAC AG-39). The mutant p53 allele was
identified using the following oligonucleotides: (59-CTT GGG TGG AGA GGC TAT
TCG-39) and (59-GTC GGG CAT GCG CGC CTT GAG-39). The qk
v mutation was
amplified using primers directed against the breakpoint (59-TCT AAA GAG CAT
TTT CGA AGT-39) and (59-TTG CTA ACT GAA TAT TAC T-39).
Immunohistochemistry. Mice were anaesthetized with isoflurane and perfused with
ice-cold phosphate buffered saline followed by 4% paraformaldehyde. Brains were
cryoprotected in 30% sucrose overnight and embedded in OCT compound (Tissue-
Tek, Markham, ON) over dry ice in acetone. Tissues were cryostat sectioned at a
thicknessof10mmandcollectedon1/1slides(Fisher,Ottawa,ON).Tissuesections
wereblockedin10%goatseruminTris-bufferedsaline10.5%TritonX-100for1hr
followed by incubation with primary antibodies overnight at room temperature.
Slides were incubated with Alexa-flour 488 or 546 Immunoglobulin G (Invitrogen,
Carlsbad,CA)atadilutionof1:400for4hr.Corpuscallosumthicknesswasvisualized
by MBP staining and quantified for 4 different areas using Axiovision software
(Zeiss). P14 and P30 mice cerebellar coronal sections were evaluated at bregma
,25.8 mm, and representative images were taken of the simple lobule adjacent to
the primary fissure. Purkinje cell linear density was quantified for 3 different areas
using Axiovision software. Purkinje cell linear density was quantified as Calbindin-
positive cell bodies/mm Purkinje cell layer. Statistical significance was calculated
according to a two-sample two-tailed paired student t-test.
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